# OnCo record b-rare-cancers (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-rare-cancers/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-rare-cancers" ;
  schema:name "Rare and paediatric cancers without markets"@en ;
  schema:description "Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in."@en ;
  schema:url <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.ejca.2011.08.008>, <https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology>, <https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer> ;
  onco:related <https://onco.cc/ideas/idea-menin-infant-all/>, <https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/>, <https://onco.cc/ideas/idea-tcr-t-beyond-hla-a2/>, <https://onco.cc/ideas/idea-bio2-rare-cancer-umbrella-platform/>, <https://onco.cc/ideas/idea-bio2-n-of-1-framework/>, <https://onco.cc/ideas/idea-bio2-paediatric-first-development/>, <https://onco.cc/ideas/idea-bio2-rare-cancer-telepathology-network/>, <https://onco.cc/ideas/idea-bio2-functional-precision-rare/>, <https://onco.cc/ideas/idea-bio2-rare-cancer-prize-fund/>, <https://onco.cc/ideas/idea-bio2-registry-embedded-randomisation/>, <https://onco.cc/ideas/idea-bio2-patient-partnered-rare-commons/>, <https://onco.cc/ideas/idea-bio2-mechanism-defined-baskets/>, <https://onco.cc/ideas/idea-bio2-shared-compound-access-pool/>, <https://onco.cc/ideas/idea-bio2-bayesian-borrowing-acceptance/>, <https://onco.cc/ideas/idea-bio2-rare-tumour-model-bank/>, <https://onco.cc/ideas/idea-moon-rare-cancer-global-network/>, <https://onco.cc/ideas/idea-moon-open-source-oncology-drug-discovery/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/thyroid/> ;
  onco:technologies <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/tandem-transplant/> ;
  onco:targets <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/gd2/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/kmt2a/> ;
  onco:drugs <https://onco.cc/drugs/tovorafenib/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/drugs/nirogacestat/>, <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/revumenib/> ;
  onco:companies <https://onco.cc/companies/y-mabs/>, <https://onco.cc/companies/day-one-biopharmaceuticals/>, <https://onco.cc/companies/springworks/>, <https://onco.cc/companies/us-worldmeds/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/curie-nki-eortc/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/sarcoma-histotype-tailoring/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/fnclcc-grade/> ;
  onco:trials <https://onco.cc/trials/defi/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/trials/euro-ewing-2012/>, <https://onco.cc/trials/anbl0032/>, <https://onco.cc/trials/hr-nbl1/>, <https://onco.cc/trials/interfant-06/>, <https://onco.cc/trials/naxitamab-201/>, <https://onco.cc/trials/nmtrc003/>, <https://onco.cc/trials/aall1731/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gatta-eur-j-cancer/> .